New Delhi: The expert panel of Drug Controller General of India (DCGI) on Thursday recommended that emergency use authorization be granted to the COVID-19 vaccine Corbevax for children in the age group of 5 to 12 years.
Corbevax, developed by Hyderabad-based firm Biological-E, is India’s first indigenously-developed RBD protein sub-unit vaccine against the coronavirus.
It is being administered to children in the age group of 12 to 14 from March 16, 2022.
Meanwhile, the government panel has sought more data from Bharat Biotech before granting emergency use approval to Covaxin among children aged 5-12.
The 5-12 age group is yet to brought under the nationwide inoculation drive.
